A series of agonists or inhibitors targeting key metabolic enzymes in tumor cells have been under clinical trials, including those in TCA cycle.5 For instance, CPI-613, a lipoamide mimic reducing PDH activity used in this study, weakened the glucose uptake of tumor cells significantly and exerted non-toxic effects to normal counterparts in preclinical study, which were also verified in breast and hematological malignancies in clinical trials. The gene discussed is PDP1; the disease is neoplasm.